Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-549	MK2206	1	72	sigmoid	sigmoid	BT549 MK-2206 0 1 72	8	1.811	Inf	0.632	0.189	0.103	0.58	0.8	0.911	0.000695	NA	Inf	0.692	0.839	0.101	0.642	0.73	0.911	0.000717	NA
BT-549	AZD-6482	2	72	sigmoid	sigmoid	BT549 AZD6482 0 2 72	8	1.973	9.15	0.635	0.112	120.0	-1.0	0.426	0.951	0.000115	NA	19.4	0.672	0.895	19.4	0.0	0.437	0.946	0.000154	NA
BT-20	Torin2	3	72	sigmoid	sigmoid	BT20 Torin2 0 3 72	8	2.458	0.019	-0.64	0.751	0.234	-1.0	0.438	0.959	6.92e-05	NA	0.0147	0.0148	0.379	0.0123	0.0598	0.727	0.977	1.28e-05	NA
BT-20	Trametinib	3	72	sigmoid	sigmoid	BT20 trametinib 0 3 72	8	2.539	Inf	0.64	0.208	0.104	0.541	0.392	0.967	3.69e-05	NA	Inf	0.604	0.761	0.0656	0.513	0.391	0.964	4.56e-05	NA
HCC38	AS605240	2	72	sigmoid	sigmoid	HCC38 AS-605240 0 2 72	8	2.200	17.4	0.642	0.114	4.07	0.256	0.493	0.936	0.000265	NA	46.2	0.648	0.882	1.68	0.411	0.522	0.929	0.000356	NA
HCC70	PIK-93	2	72	sigmoid	sigmoid	HCC70 PIK-93 0 2 72	8	1.705	4.34	0.647	0.0132	9.3	-1.0	1.44	0.888	0.0014	NA	6.01	0.718	0.991	6.01	0.0	1.49	0.872	0.00208	NA
HCC1806	ZSTK474	3	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 3 72	8	3.162	Inf	0.654	0.0322	1.18	0.65	4.68	0.99	1.03e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC38	PIK-93	2	72	sigmoid	sigmoid	HCC38 PIK-93 0 2 72	8	2.107	31.9	0.661	0.0151	2.16	0.497	1.86	0.922	0.000468	NA	Inf	0.676	0.987	1.97	0.545	1.87	0.907	0.000813	NA
Hs 578T	Everolimus	3		flat	flat	Hs578T everolimus 3	8	2.848	Inf	0.664	0.299	0.0	0.664	0.01	0.475	0.144	0.702	Inf	0.592	0.631	0.0	0.592	0.01	0.486	0.136	0.632
Hs 578T	MK2206	2		sigmoid	sigmoid	Hs578T MK-2206 2	8	2.530	Inf	0.664	0.131	0.0699	0.752	1.34	0.75	0.0156	NA	Inf	0.628	0.848	0.0616	0.717	1.21	0.767	0.0126	NA
Hs 578T	AZD-6482	3		sigmoid	sigmoid	Hs578T AZD6482 3	8	2.832	6.09	0.667	0.0547	24.1	-1.0	0.799	0.989	1.5e-06	NA	5.12	0.597	0.93	5.12	0.0	0.861	0.985	3.33e-06	NA
Hs 578T	Alpelisib	2		flat	flat	Hs578T alpelisib 2	8	2.513	Inf	0.668	0.131	0.0	0.668	0.01	0.599	0.0647	0.856	Inf	0.634	0.847	0.0	0.634	0.01	0.541	0.0969	0.833
BT-549	AZD-6482	1	72	sigmoid	sigmoid	BT549 AZD6482 0 1 72	8	1.798	27.5	0.671	0.115	4.1	0.299	0.478	0.992	4.23e-07	NA	164.0	0.723	0.901	4.18	0.408	0.461	0.992	5.34e-07	NA
HCC70	Everolimus	2	72	flat	flat	HCC70 everolimus 0 2 72	8	1.730	Inf	0.674	0.227	0.0	0.674	0.01	0.271	0.388	0.766	Inf	0.735	0.812	0.0	0.735	0.01	0.264	0.399	0.807
Hs 578T	Sirolimus	3		flat	flat	Hs578T rapamycin 3	8	2.836	Inf	0.675	0.309	0.0	0.675	0.01	-1.79	1.0	0.691	Inf	0.604	0.621	0.0	0.604	0.01	-3.02	1.0	0.621
BT-20	BX-912	2	72	flat	flat	BT20 BX-912 0 2 72	8	1.873	Inf	0.683	0.213	0.0	0.683	0.01	0.118	0.686	0.777	Inf	0.724	0.81	0.0	0.724	0.01	0.111	0.702	0.802
HCC70	Sirolimus	2	72	flat	flat	HCC70 rapamycin 0 2 72	8	1.762	Inf	0.685	0.257	0.0	0.685	0.01	0.531	0.103	0.741	Inf	0.739	0.785	0.0	0.739	0.01	0.524	0.108	0.783
Hs 578T	TGX221	1		sigmoid	sigmoid	Hs578T TGX-221 1	8	2.019	14.6	0.686	0.0936	23.9	-0.133	0.479	0.995	1.07e-07	NA	27.2	0.708	0.91	11.5	0.171	0.484	0.995	1.48e-07	NA
BT-549	PIK-93	2	72	sigmoid	sigmoid	BT549 PIK-93 0 2 72	8	1.983	7.03	0.687	0.0641	29.9	-1.0	0.759	0.956	8.81e-05	NA	10.4	0.713	0.939	10.4	0.0	0.788	0.949	0.000136	NA
BT-549	PIK-93	1	72	sigmoid	sigmoid	BT549 PIK-93 0 1 72	8	1.777	Inf	0.691	0.0438	1.77	0.561	1.47	0.989	1.31e-06	NA	Inf	0.742	0.963	1.64	0.646	1.47	0.988	1.83e-06	NA
HCC38	MK2206	1	72	sigmoid	sigmoid	HCC38 MK-2206 0 1 72	8	1.789	19.4	0.698	0.0995	320.0	-0.949	0.38	0.956	8.33e-05	NA	61.8	0.746	0.914	61.8	0.0	0.386	0.951	0.000115	NA
HCC70	TGX221	3	72	sigmoid	sigmoid	HCC70 TGX-221 0 3 72	8	2.459	Inf	0.7	0.0886	0.338	0.675	1.11	0.971	2.48e-05	NA	Inf	0.671	0.9	0.295	0.648	1.13	0.966	3.94e-05	NA
HCC70	Omipalisib	2	72	sigmoid	sigmoid	HCC70 omipalisib 0 2 72	8	1.682	0.00746	-0.705	1.01	0.0241	-0.703	0.749	0.991	6.69e-07	NA	0.0135	0.0399	0.359	0.0121	0.0458	0.852	0.989	1.45e-06	NA
Hs 578T	Alpelisib	3		sigmoid	sigmoid	Hs578T alpelisib 3	8	2.856	Inf	0.712	0.0759	0.872	0.616	0.828	0.963	5.21e-05	NA	Inf	0.641	0.901	0.65	0.553	0.853	0.955	8.85e-05	NA
BT-549	MK2206	3	72	sigmoid	sigmoid	BT549 MK-2206 0 3 72	8	1.685	Inf	0.714	0.131	0.123	0.711	3.44	0.953	0.000102	NA	Inf	0.771	0.895	0.123	0.768	3.25	0.949	0.000136	NA

|<
<<
Previous
Page 12 of 18
Next
>>
>
276 to 300 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)